Breast cancer in young women;Le cancer du sein chez la femme jeune

Revue Medicale de Liege

Volumn 66, Issue 5-6, 2011, Pages 397-399

  Andre Ch ^a   Collignon, J ^a   Rorive, A ^a   Martin, M ^a   Maweja, S ^a   Lifrange, E ^a   Coucke, Ph ^a   Jerusalem, G ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Biopathological parameters; Breast cancer; Specific management; Young women

Indexed keywords

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; HUMAN; MASTECTOMY; REVIEW; WOMEN'S HEALTH;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DECISION MAKING; FEMALE; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; TAMOXIFEN; YOUNG ADULT;

EID: 80051680302     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Pollan M. - Epidemiology of breast cancer in young women. Breast Cancer Res Treat, 2010, 123, 3-6.
2. Bouchardy C, Fioretta G, Verkooijen HM, et al. - Recent increase of breast cancer incidence among women under the age of forty. Br J Cancer, 2007, 96, 1743-1746. (Pubitemid 46847205)
3. ème journée de la Société française de Sénologie et de Pathologie mammaire, 2010.
4. Cancello G, Maisonneuve P, Rotmensz N, et al. - Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol, 2010, 21, 1974-1981.
5. Silver DP, Richardson AL, Eklund AC, et al. - Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol, 2010, 28, 1145-1153.
6. Ashworth A. - A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol, 2008, 26, 3785-3790.
7. Voduc KD, Cheang MC, Tyldesley S, et al. - Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol, 2010, 28, 1684-1691.
8. Katz SJ, Lantz PM, Janz NK, et al. - Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol, 2005, 23, 5526-5533.
9. Coucke PA, Vavassis P, Vanderick J. - Tumor margin after conservative breast cancer surgery for early disease : an issue or not? BJMO, 2009, 3, 93-100.
10. Chang HR. - Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer, 2010, 116, 2856-2867.
11. Sardanelli F, Boetes C, Borisch B, et al. - Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer, 2010, 46, 1296-1316.
12. Bonilla L, Ben-Aharon I, Vidal L, et al. - Dose-dense chemotherapy in nonmetastatic breast cancer : a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst, 2010, 102, 1845-1854.
13. Romond EH, Perez EA, Bryant J, et al. - Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 2005, 353, 1673-1684. (Pubitemid 41464706)
14. Chang HR, Slamon D, Prati R. - A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer : response and cardiotoxicity. J Clin Oncol, 2006, 24, abstract10515.
15. Ismail-Khan R, Minton S, Cox C, et al. - Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer, 2008, 26, abstract 524.
16. Azim HA Jr, Azambuja E, Colozza M, et al. - Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol, 2011, Feb 2. Epub ahead of print.